Gene · 79679
VTCN1: V-set domain containing T cell activation inhibitor 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. VTCN1: V-set domain containing T cell activation inhibitor 1. Genes, record 79679. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/79679
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q7Z7D3 | V-set domain-containing T-cell activation inhibitor 1 | 282 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents499
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4831196 A2 | 2026-10-28 | 7 | Q7Z7D3 | Espacenet |
| EP 4824100 A2 | 2026-10-21 | 1 | Q7Z7D3 | Espacenet |
| WO 2026151884 A1 | 2026-07-16 | 1 | Q7Z7D3 | Espacenet |
| JP 2026090543 A | 2026-06-02 | 180 | Q7Z7D3 | Espacenet |
| JP 2026082984 A | 2026-05-19 | 59 | Q7Z7D3 | Espacenet |
| US 12624087 B2 | 2026-05-12 | 7 | Q7Z7D3 | Espacenet |
| US 12612446 B2 | 2026-04-28 | 449 | Q7Z7D3 | Espacenet |
| JP 2026053725 A | 2026-03-25 | 1 | Q7Z7D3 | Espacenet |
| JP 2025166053 A | 2025-11-05 | 7 | Q7Z7D3 | Espacenet |
| JP 2025148471 A | 2025-10-07 | 449 | Q7Z7D3 | Espacenet |
1 to 10 of 499
See all 499 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants878
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | VTCN1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 18 | 2025 |
| P30CA016359 | Cancer Center Support Grant | 17 | 2025 |
| R01CA175495 | The B7x pathways in the tumor microenvironment | 15 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 11 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 11 | 2025 |
| P50CA196530 | Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer | 10 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 8 | 2025 |
| P50CA101942 | DF/HCC Kidney Cancer SPORE (supplement) | 6 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 6 | 2025 |
| P50CA121974 | Yale SPORE in Skin Cancer | 5 | 2025 |
1 to 10 of 878Source NIH's project files
See all 878 nih grantsPapers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Special tumor entities : New results at the 2026 ASCO Annual Meeting]. | HNO | 2026 | 42814119 | PubTator, text mining | PubMed |
| Time to Rethink Pathology Reporting in Adenoid Cystic Carcinoma. | Head Neck | 2026 | 42811719 | PubTator, text mining | PubMed |
| A study on the mechanism of action of B7H4 in HER2-positive gastric cancer and its sensitivity to trastuzumab therapy. | Transl Cancer Res | 2026 | 42724573 | PubTator, text mining | PubMed |
| Membrane and soluble VTCN1 (B7H4) converge on Src signaling to mediate gemcitabine resistance in intrahepatic cholangiocarcinoma. | Theranostics | 2026 | 42708082 | PubTator, text mining | PubMed |
| Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma. | Res Sq | 2026 | 42687902 | PubTator, text mining | PubMed |
| Nardilysin: classical functions and new horizons in autoimmunity. | Front Immunol | 2026 | 42676835 | PubTator, text mining | PubMed |
| AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. | Nat Commun | 2026 | 42624861 | PubTator, text mining | PubMed |
| European Society for Medical Oncology Gynaecological Cancers Congress 2026: key scientific advances from the oral sessions. | Int J Gynecol Cancer | 2026 | 42624675 | PubTator, text mining | PubMed |
| B7-H4 enrichment represents a site-specific immunotherapy target in small bowel gastrointestinal stromal tumors. | bioRxiv | 2026 | 42620335 | PubTator, text mining | PubMed |
| Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges. | EClinicalMedicine | 2026 | 42534594 | PubTator, text mining | PubMed |
1 to 10 of 2,409
See all 2,409 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/79679
GET https://conductscience.org/api/genes/v1/79679/patents?page=2